Companies / AN1

ANAGENICS LIMITED

ASX:AN1Pharmaceuticals, Biotechnology & Life Sciences
985.5M shares on issueASX (delayed) · as of 28 July 2026$0.006price · delayed$5.9Mmarket cap · indicative
C
Dilution grade

Runway under 2 quarters; share count grew 114% in 24 months; 1 cash raise in 24 months

Cash runway1.2 quarters of funding
Share-count growth (24m)113.6%
Raise cadence (24m)1 cash raise
Options & rights overhang1.3% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

ANAGENICS LIMITED's ordinary share count grew 113.6% between April 2024 and February 2026, to 985M shares. The company raised capital once in that period for total proceeds of A$2.2M, most recently in December 2025 (A$2.2M). Options and rights on issue could convert into 13M new shares, equal to 1.3% of the current share count, and none are in the money at the current price. At the March 2026 quarter the company reported A$406K in available cash, representing 1.2 quarters of funding at its recent spending rate. There are no proposed securities issues (Appendix 3B) pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
1.3%
Max option dilution
0.0%
ITM option dilution
1
Raises · last 12 months
1.2 qtrs
Cash cover · under 2 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 985.5M per ASX (delayed) (28 July 2026).
571.4M723.4M875.4MDec 24Sept 25July 26Cash raise · 5 Dec 2025

Cash runway

1.2 qtrs
Less than two quarters of funding at the recent spend rate — near-term funding pressure.
$406k available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
17 Apr 20263H · cancellationAN1 : ORDINARY FULLY PAID985.5MAppendix 3H
12 Feb 20263G · unquotedAN1 : ORDINARY FULLY PAID985.5MAppendix 3G
8 Feb 20262A · quoted issueAN1 : ORDINARY FULLY PAID985.5MAppendix 2A
29 Jan 20263H · cancellationAN1 : ORDINARY FULLY PAID570.8MAppendix 3H
29 Jan 20263H · cancellationAN1 : ORDINARY FULLY PAID570.8MAppendix 3H
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

1 cash raise in the last 24 months · 1 in the last 12 months

$2.3M
Capital raise
5 Dec 2025
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

1.3%
Total overhang · of current shares
0.0%
In the money · at current price
12.9M
Potential new shares
—
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
26 Feb 2026Alexander BeardBuy2.9M—$20k3Y notice
16 May 2025Alexander BeardBuy56k——3Y notice
14 May 2025Alexander BeardBuy227k——3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

27 July 2026Change of Auditor
27 Apr 2026$PAN1 - Appendix 4C & Activity Report for Q3 FY2026
17 Apr 2026Notification of cessation of securities - AN1
1 Mar 2026Appendix 3X MR JOSHUA GORDON
1 Mar 2026AN1 - Director Appointment
26 Feb 2026Change of Director's Interest Notice
24 Feb 2026AN1 - 1H FY26 Presentation
24 Feb 2026$PAnagenics - 1H FY26 Result Highlights
24 Feb 2026Anagenics - 1H26 HY Report DEC 2025
24 Feb 2026$PAppendix 4D 1H FY26 DEC 2025
12 Feb 2026Becoming a substantial holder
12 Feb 2026Becoming a substantial holder
12 Feb 2026Notification regarding unquoted securities - AN1
9 Feb 2026Ceasing to be a substantial holder from FOS
9 Feb 2026Change in substantial holding from HNG
8 Feb 2026Application for quotation of securities - AN1
29 Jan 2026Notification of cessation of securities - AN1
29 Jan 2026Notification of cessation of securities - AN1
29 Jan 2026$PAppendix 4C & Activity Report for Q2 FY2026
28 Jan 2026Results of Meeting

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.